| Statins in the 21st century: end of the simple story? | |
| | |
MedLine Citation:
|
PMID: 11772284 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The development of the HMG-CoA reductase inhibitors (the statins) has lead to important advances in the management of cardiovascular disease. There have several landmark mortality and morbidity clinical trials with the statins. The 4S (Scandinavian Simvastatin Survival Study) was the first large-scale randomised cholesterol-lowering trial to show a decrease in mortality. In patients with coronary heart disease and relatively high cholesterol, simvastatin decreased mortality, hospital stays, the risk of undergoing myocardial re-vascularisation, stroke and transient ischaemic attack. The CARE (Cholesterol and Recurrent Events) trial showed that lowering average cholesterol levels after myocardial infarction with pravastatin reduced a composite primary end point of coronary mortality and myocardial infarction, coronary bypass surgery, angioplasty and strokes. The LIPID (Long-term Intervention with Pravastatin in Ischaaemic Disease) study showed that lowering average cholesterol levels after previous myocardial infarction or unstable angina reduced mortality. WOSCOPS (The West of Scotland Coronary Prevention Study) was the first trial to demonstrate the benefit of pravastatin, as primary prevention for cardiovascular disease, in men with high cholesterol levels. AFCAPS/Tex CAPS (The Air Force/Texas Coronary Atherosclerosis Prevention Study) showed that the benefits of lowering cholesterol levels were also evident in healthy men and women who initially had average cholesterol levels. Rather surprisingly the reductions in mortality and morbidity with statins are only associated with small improvements in coronary angiographic findings. A preliminary study indicated than lovastatin prevented restenosis, but larger and better-controlled studies indicate that the statins do not have beneficial effects in restenosis. Effects other than lipid-lowering or as a consequence of their lipid-lowering may contribute to the beneficial effects of statins. These effects include improvement in vascular endothelial function, cardiac remodelling, changes in blood rheology, anti-oxidant, anti-inflammatory and anti-hypertensive actions. |
| | |
Authors:
|
S A Doggrell |
Related Documents
:
|
21860554 - Preoperative aspirin resistance does not increase myocardial injury during off-pump cor... 20031564 - Polymorphism in the cetp gene region, hdl cholesterol, and risk of future myocardial in... 10067164 - Macroscopic distribution of coronary atherosclerotic lesions in cholesterol-fed rabbits. 6504864 - Prognostic importance of cholesterol levels after myocardial infarction. 7604374 - Late survival risk factors for abdominal aortic aneurysm repair: experience from fourte... 11485024 - Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ectim... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 10 ISSN: 1354-3784 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2001 Sep |
Date Detail:
|
Created Date: 2002-01-04 Completed Date: 2002-03-15 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1755-66 Citation Subset: IM |
Affiliation:
|
Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Trials as Topic
/
methods*,
statistics & numerical data,
trends* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Hypercholesterolemia / blood, drug therapy*, enzymology, epidemiology |
| Chemical | |
Reg. No./Substance:
|
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunoco...
Next Document: Antiglucocorticoid drugs in the treatment of depression.